IPSEN (IPN.PA) Stock Fundamental Analysis
EPA:IPN - Euronext Paris - Matif - FR0010259150 - Common Stock - Currency: EUR
We assign a fundamental rating of 5 out of 10 to IPN. IPN was compared to 51 industry peers in the Pharmaceuticals industry. IPN has an average financial health and profitability rating. IPN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
IPN had positive earnings in the past year.
IPN had a positive operating cash flow in the past year.
IPN had positive earnings in each of the past 5 years.
In the past 5 years IPN always reported a positive cash flow from operatings.
1.2 Ratios
IPN has a Return On Assets (5.37%) which is comparable to the rest of the industry.
IPN has a Return On Equity of 8.27%. This is comparable to the rest of the industry: IPN outperforms 43.14% of its industry peers.
IPN has a better Return On Invested Capital (13.22%) than 66.67% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IPN is in line with the industry average of 14.80%.
The last Return On Invested Capital (13.22%) for IPN is above the 3 year average (12.97%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.37% | ||
| ROE | 8.27% | ||
| ROIC | 13.22% |
ROA(3y)9.04%
ROA(5y)10.56%
ROE(3y)14.84%
ROE(5y)18.77%
ROIC(3y)12.97%
ROIC(5y)15.34%
1.3 Margins
Looking at the Profit Margin, with a value of 9.68%, IPN is in line with its industry, outperforming 45.10% of the companies in the same industry.
IPN's Profit Margin has declined in the last couple of years.
IPN has a Operating Margin (22.15%) which is in line with its industry peers.
IPN's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 82.69%, IPN belongs to the best of the industry, outperforming 84.31% of the companies in the same industry.
In the last couple of years the Gross Margin of IPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.15% | ||
| PM (TTM) | 9.68% | ||
| GM | 82.69% |
OM growth 3Y-13.94%
OM growth 5Y-4.28%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IPN is creating some value.
Compared to 1 year ago, IPN has more shares outstanding
IPN has about the same amout of shares outstanding than it did 5 years ago.
IPN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.21 indicates that IPN is not in any danger for bankruptcy at the moment.
IPN has a better Altman-Z score (4.21) than 76.47% of its industry peers.
IPN has a debt to FCF ratio of 3.21. This is a good value and a sign of high solvency as IPN would need 3.21 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.21, IPN is doing good in the industry, outperforming 64.71% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that IPN is not too dependend on debt financing.
The Debt to Equity ratio of IPN (0.09) is better than 78.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 3.21 | ||
| Altman-Z | 4.21 |
ROIC/WACC1.74
WACC7.61%
2.3 Liquidity
IPN has a Current Ratio of 1.34. This is a normal value and indicates that IPN is financially healthy and should not expect problems in meeting its short term obligations.
IPN has a Current ratio (1.34) which is comparable to the rest of the industry.
A Quick Ratio of 1.15 indicates that IPN should not have too much problems paying its short term obligations.
IPN has a better Quick ratio (1.15) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.34 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
IPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.24%, which is quite good.
Measured over the past years, IPN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.79% on average per year.
Looking at the last year, IPN shows a quite strong growth in Revenue. The Revenue has grown by 8.11% in the last year.
IPN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.83% yearly.
EPS 1Y (TTM)12.24%
EPS 3Y4.15%
EPS 5Y8.79%
EPS Q2Q%24.21%
Revenue 1Y (TTM)8.11%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%8.28%
3.2 Future
Based on estimates for the next years, IPN will show a small growth in Earnings Per Share. The EPS will grow by 5.18% on average per year.
IPN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.92% yearly.
EPS Next Y1.78%
EPS Next 2Y4.08%
EPS Next 3Y5.64%
EPS Next 5Y5.18%
Revenue Next Year6.73%
Revenue Next 2Y5.94%
Revenue Next 3Y6.33%
Revenue Next 5Y4.92%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.90 indicates a reasonable valuation of IPN.
IPN's Price/Earnings ratio is rather cheap when compared to the industry. IPN is cheaper than 82.35% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.34, IPN is valued rather cheaply.
IPN is valuated reasonably with a Price/Forward Earnings ratio of 9.73.
IPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IPN is cheaper than 74.51% of the companies in the same industry.
IPN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.9 | ||
| Fwd PE | 9.73 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IPN is valued cheaper than 92.16% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IPN is valued a bit more expensive than 62.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.09 | ||
| EV/EBITDA | 5.57 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of IPN may justify a higher PE ratio.
PEG (NY)5.56
PEG (5Y)1.13
EPS Next 2Y4.08%
EPS Next 3Y5.64%
5. Dividend
5.1 Amount
IPN has a Yearly Dividend Yield of 1.34%. Purely for dividend investing, there may be better candidates out there.
IPN's Dividend Yield is comparable with the industry average which is at 2.92.
With a Dividend Yield of 1.34, IPN pays less dividend than the S&P500 average, which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.34% |
5.2 History
The dividend of IPN has a limited annual growth rate of 3.72%.
Dividend Growth(5Y)3.72%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
28.79% of the earnings are spent on dividend by IPN. This is a low number and sustainable payout ratio.
The dividend of IPN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP28.79%
EPS Next 2Y4.08%
EPS Next 3Y5.64%
EPA:IPN (6/18/2025, 7:00:00 PM)
101.7
-1 (-0.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.53%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap8.52B
Analysts68.42
Price Target127.41 (25.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.34% |
Yearly Dividend1.2
Dividend Growth(5Y)3.72%
DP28.79%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.32%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.9 | ||
| Fwd PE | 9.73 | ||
| P/S | 2.38 | ||
| P/FCF | 64.09 | ||
| P/OCF | 9.31 | ||
| P/B | 2.04 | ||
| P/tB | 8.84 | ||
| EV/EBITDA | 5.57 |
EPS(TTM)10.27
EY10.1%
EPS(NY)10.45
Fwd EY10.28%
FCF(TTM)1.59
FCFY1.56%
OCF(TTM)10.92
OCFY10.74%
SpS42.65
BVpS49.89
TBVpS11.5
PEG (NY)5.56
PEG (5Y)1.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.37% | ||
| ROE | 8.27% | ||
| ROCE | 16.05% | ||
| ROIC | 13.22% | ||
| ROICexc | 15.36% | ||
| ROICexgc | 63.33% | ||
| OM | 22.15% | ||
| PM (TTM) | 9.68% | ||
| GM | 82.69% | ||
| FCFM | 3.72% |
ROA(3y)9.04%
ROA(5y)10.56%
ROE(3y)14.84%
ROE(5y)18.77%
ROIC(3y)12.97%
ROIC(5y)15.34%
ROICexc(3y)20.33%
ROICexc(5y)25.52%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)15.75%
ROCE(5y)18.64%
ROICexcg growth 3Y-59.92%
ROICexcg growth 5Y-22.83%
ROICexc growth 3Y-29.05%
ROICexc growth 5Y-11.89%
OM growth 3Y-13.94%
OM growth 5Y-4.28%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
F-Score6
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 3.21 | ||
| Debt/EBITDA | 0.26 | ||
| Cap/Depr | 110.85% | ||
| Cap/Sales | 21.89% | ||
| Interest Coverage | 96.55 | ||
| Cash Conversion | 61.13% | ||
| Profit Quality | 38.45% | ||
| Current Ratio | 1.34 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 4.21 |
F-Score6
WACC7.61%
ROIC/WACC1.74
Cap/Depr(3y)131.36%
Cap/Depr(5y)124.73%
Cap/Sales(3y)11.81%
Cap/Sales(5y)11.18%
Profit Quality(3y)85.87%
Profit Quality(5y)89.99%
High Growth Momentum
Growth
EPS 1Y (TTM)12.24%
EPS 3Y4.15%
EPS 5Y8.79%
EPS Q2Q%24.21%
EPS Next Y1.78%
EPS Next 2Y4.08%
EPS Next 3Y5.64%
EPS Next 5Y5.18%
Revenue 1Y (TTM)8.11%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%8.28%
Revenue Next Year6.73%
Revenue Next 2Y5.94%
Revenue Next 3Y6.33%
Revenue Next 5Y4.92%
EBIT growth 1Y34.12%
EBIT growth 3Y-6.06%
EBIT growth 5Y1.3%
EBIT Next Year27.18%
EBIT Next 3Y13.1%
EBIT Next 5Y6.78%
FCF growth 1Y-80.91%
FCF growth 3Y-35.67%
FCF growth 5Y-17.46%
OCF growth 1Y4.09%
OCF growth 3Y-0.07%
OCF growth 5Y7.84%